Summary
Mafosfamide-cyclohexylamine is a new oxazaphosphorine derivative. It was chosen for phase-I clinical testing because of an expected higher therapeutic index and lack of complete cross resistance in animal tumors compared to cyclophosphamide. The schedule consisted of a single iv dose repeated every three weeks. The compound was found to cause as it's dose limiting toxicity severe pain along the injected vein and acute irritation of mucous membranes. The maximal tolerated dose was around 1000 mg/m2 given as a slow infusion over 2–3 hours. Hematological toxicity was mild. A limited phase-I study with the lysine salt of mafosfamide showed an identical type of toxicity. Mafosfamide given iv in a high-dose intermittent schedule is of little interest for further clinical trials.
It is probable, that the severe venous pain and the mucosal irritation are caused by the high local concentration of 4-hydroxy-cyclophosphamide or by a metabolite. An oxazaphosphorine derivative undergoing slower hydrolysis therefore leading to lower active drug concentrations within the injected vein may be more promising.
Similar content being viewed by others
References
Pohl J (1983): Asta-Z-7557, Summary for Investigators. Preclinical Report, Asta-Werke
Atassi G, Hilgard P, Pohl J: Antineoplastic activity of Asta-Z-7557, NSC-345842 (INN mafosfamide) on transplantable murine tumors. Invest New Drugs 2:169–173, 1984
Pohl J, Hilgard P, Jahn W, Zechel HJ: Experimental toxicology of Asta-Z-7557 (INN mafosfamide). Invest New Drugs 2:201–206, 1984
Carter SK: Study design principles for the clinical evaluation of new drugs as developed by the chemotherapy program of the National Cancer Institute; in M Staquet (ed): The design of clinical, trials in cancer therapy. Editiones Scientifiques Européenes, Brüssel, 1972, pp 242–289
Herve P, Cahn JY, Plouvier E, Flesch M, Tamayo E, Leconte Des Floris R, Peters A: Autologous bone marrow transplantation for acute leukemia using transplant chemo-purified with metabolite of oxazaphosphorines (Asta Z 7557, INN mafosfamide). First clinical results. Invest New Drugs 2:245–252, 1984
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Bruntsch, U., Groos, G., Hiller, T.A. et al. Phase-I study of mafosfamide-cyclohexylamine (ASTA-Z-7557, NSC 345 842) and limited phase-I data on mafosfamide-lysine. Invest New Drugs 3, 293–296 (1985). https://doi.org/10.1007/BF00179434
Issue Date:
DOI: https://doi.org/10.1007/BF00179434